This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT02171260
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of 14C-Perampanel in Healthy Male Subjects
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT02116907
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States
A Study to Determine the Effect of a High-Fat Meal on the Rate and Extent of E2006 Absorption in Healthy Subjects
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT02089412
- Locations
- 🇺🇸
PPD Development LLC, Austin, Texas, United States
A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2014-03-13
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT02085967
- Locations
- 🇺🇸
PPD Development LLC, Austin, Texas, United States
A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT02055703
- Locations
- 🇺🇸
WCT Early Development, San Antonio, Texas, United States
An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02046213
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects
- Conditions
- Healthy Volunteers
- Interventions
- Drug: PlaceboDrug: E2006 2.5 mgDrug: E2006 10 mgDrug: E2006 25 mg
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02039089
A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02039076
- Locations
- 🇺🇸
Parexel International Early Development Clinical Units, Glendale, California, United States
A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT02033902
- Locations
- 🇬🇧
Eisai Site# 1606, Truro, United Kingdom
🇦🇹Universitatsklinikum Innsbruck, Innsbruck, Austria
🇦🇹Kepler Universitätsklinikum, Linz, Austria
Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT02022956
- Locations
- 🇺🇸
Worlwide Clinical Trials, San Antonio, Texas, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States